Shire-Takeda Deal Gets Phase I Conditional European Approval
Zacks Investment Research | Nov 20, 2018 09:36PM ET
Shire Plc (NASDAQ:SHPG) announced that the European Union antitrust regulators have granted a phase I conditional approval to Takeda Pharmaceutical Co. Ltd.'s $62-billion bid to acquire the former. The European Commission has approved the deal subject to Shire selling an inflammatory bowel disease treatment, called SHP647 that could compete with a Takeda-marketed product Entyvio (vedolizumab)if SHP647 gets approved and hits the market.
Takeda stated that the clearance from the European Commission was the final regulatory approval required to proceed with its acquisition of Shire. Takeda had announced the acquisition in May 2018.
The acquisition is subject to certain other conditions, including receipt of approval from the shareholders of Shire and Takeda, the satisfaction or, where applicable, waiver of the other conditions set out in the Scheme Document, and the sanction of the Court. Assuming these conditions are met, Shire and Takeda confirmed that the acquisition will close on Jan 8, 2019.
Both the companies are leaders in their therapeutic areas and also have an attractive geographic footprint. Thus, the combined group will be better positioned to deliver highly-innovative medicines and transformative care providing better health and a brighter future for patients around the world
Shares of the company have increased 14.5% year to date, against the Zacks Investment Research
Get The News You Want
Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.